CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗胰腺癌：当前证据综述
英文原题：Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence.
查看英文原题
Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已经彻底改变了恶性和非恶性疾病的治疗。CAR是表达在经基因修饰的免疫效应细胞（包括T细胞、自然杀伤（NK）细胞或巨噬细胞）上的合成跨膜受体，能够识别靶细胞上的特定表面抗原并将其清除。CAR修饰的免疫细胞通过多种机制介导细胞毒性抗肿瘤效应，包括穿孔素和颗粒酶途径、Fas和Fas配体（FasL）途径以及细胞因子分泌。CAR-T 策略在实体瘤中的应用前景备受期待，尤其是对标准肿瘤治疗耐药的实体瘤，如胰腺癌（PC）。本文中，我们总结了目前评估潜在肿瘤相关抗原（TAA）、CAR-T 细胞毒性及其在PC中疗效的临床前和临床研究。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of malignant and non-malignant disorders. CARs are synthetic transmembrane receptors expressed on genetically modified immune effector cells, including T cells, natural killer (NK) cells, or macrophages, which are able to recognize specific surface antigens on target cells and eliminate them.
CAR-modified immune cells mediate cytotoxic antitumor effects via numerous mechanisms, including the perforin and granzyme pathway, Fas and Fas Ligand (FasL) pathway, and cytokine secretion. High hopes are associated with the prospective use of the CAR-T strategy against solid cancers, especially the ones resistant to standard oncological therapies, such as pancreatic cancer (PC).
Herein, we summarize the current pre-clinical and clinical studies evaluating potential tumor-associated antigens (TAA), CAR-T cell toxicities, and their efficacy in PC.
论文信息
- 作者
- Czaplicka A、Lachota M、Pączek L、Zagożdżon R、Kaleta B
- 第一作者单位
- Department of Internal Medicine and Gastroenterology, Mazovian "Bródnowski" Hospital, 03-242 Warsaw, Poland.Poland
- 通讯作者单位
- Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland.Poland
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cells2024 Jan 4
- 原文标识
- PubMed 38201305 · DOI 10.3390/cells13010101
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →